Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1021 to 1035 of 1242 results for public health guidance

  1. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

  2. Neonatal parenteral nutrition (NG154)

    This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.

  3. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

  4. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued Reference number: GID-TA11178

  5. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

  6. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

  7. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

  8. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

  9. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued Reference number: GID-TA11177

  10. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Discontinued Reference number: GID-TA11338

  11. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

  12. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

  13. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

  14. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC